Friday,
November 8, 2002 |
6:00
am-6:00 pm |
Registration
Open |
7:00
am-8:00 am |
Continental
Breakfast in the Exhibit Hall |
8:00
am-8:15 am |
President's
Welcome and Keynote Address Introduction
Robert O. Dillman, MD
Hoag Cancer Center |
8:15
am-9:15 am |
Keynote
Address
The HER2 Alteration in Human Breast Cancer:
Therapeutic and Diagnostic Implications
Dennis Slamon, MD, PhD
University of California Los Angeles |
9:15
am-9:30 am |
Refreshment
Break |
9:30
am-12:15 pm |
Joint
Session: Antibodies/Immunoconjugates |
|
Co-Chairs:
Christine
A. White, MD
IDEC Pharmaceuticals Corp.
Peter McLaughlin,
MD
MD Anderson Cancer Center
|
9:30
am-9:55 am |
Zevalin:
The Radiotherapy of Non-Hodgkins Lymphoma
Christine A. White, MD
IDEC Pharmaceuticals Corp.
|
9:55
am-10:20 am |
Rixtuximab,
Spectrum of Activity, Mechanisms of Action and Resistance
Peter McLaughlin, MD
MD Anderson Cancer Center
|
10:20 am-10:45
am |
The
Role of Alemtuzumab in the Therapy of CLL
Stefan Faderl, MD
MD Anderson Cancer Center
|
10:45
am-11:10 am |
Antibody-Based
Treatment of AML
Joseph G. Jurcic, MD
Memorial Sloan-Kettering Cancer Center
|
11:10
am-11:35 am |
Mechanisms
of Action of Anti-Tumor Monoclonal Antibodies: Lessons from Apolizumab
and Immunostimulatory CpG ODN
George J. Weiner, MD
University of Iowa
|
11:35
am-11:50 am |
Humanized
Monoclonal Antibody IGN311 Targeting Lewis Y: Pharmacokinetics and
Toxicology in Rhesus Monkeys
Hans Loibner, PhD
Igeneon AG
|
11:50
am-12:05 pm |
Phenotypic
Analysis of Peripheral Blood Mononuclear Cells (PBMC) in MDX-010
(Fully Human Anti-CTLA-4 MAb) Treated Cancer Patients
Thomas A. Davis, MD
Medarex, Inc.
|
12:05
pm-12:20 pm |
ABX-EGF,
A Fully Human Anti-Epidermal Growth Factor Receptor (EGFr) Monoclonal
Antibody (Mab): Results of a Phase 1 Study and a Phase 2 Renal Cell
Cancer (RCC) Study
Kenneth A. Foon, MD
Abgenix, Inc.
|
12:15
pm-2:15 pm |
Poster
Session (authors must be present)
Box lunches will be available in the Scripps Hallway |
2:15
pm-5:00 pm |
Concurrent
Sessions 1: Engineered T Cells & IL-2 in Malignancy |
|
Co-Chairs:
Kim A. Margolin, MD
City of
Hope
Michael Jensen,
MD
City of Hope/Beckman Research Institute
|
2:15
pm – 2:40 pm |
The Role of IL-2 in Hematologic Malignancy and Hematopoietic Cell
Transplant
Kim A. Margolin, MD
City of Hope |
2:40
pm – 3:05 pm |
Adaptive
Therapy with Chimeric Immunoreceptor Re-Directed T-Cells
Michael Jensen, MD
City of Hope/Beckman Research Institute |
3:05
pm – 3:30 pm |
Mechanisms
of Tumor Recognition and Cytolysis by Ex-Vivo Expanded Cells
Michael Verneris
Stanford University |
3:30
pm – 3:50 pm |
Refreshment
Break |
3:50
pm – 4:15 pm |
Recovery
of T Cell Populations Post Transplant
Ronald E. Gress, MD
National Cancer Institute, NIH |
4:15
pm – 4:45 pm |
Lawrence
Cooper, MD, PhD
City of Hope National Medical Center |
4:45
pm – 5:00 pm |
Hydrophobically
Appended Tumor Antigens Induce High Affinity Cytotoxic T Cells from
Ovarian Tumor Associated Lymphocytes
Koichiro Kawano, MD, PhD
MD Anderson Cancer Center |
2:15
pm-5:05 pm |
Concurrent
Session 2: Vaccines and Mechanisms of Escape |
|
Co-Chairs:
Peter Hersey, MD, PhD
Newcastle
Mater Hospital
James W. Mier,
MD
Beth Israel Deaconess Medical Center
|
2:15
pm – 2:40 pm |
Resistance
Mechanisms in Melanoma Cells to Apoptosis Induced by TRAIL (TNF-related
apoptosis inducing ligand)
Peter Hersey, MD, PhD
Newcastle Mater Hospital |
2:40
pm – 3:05 pm |
Role
of PI-3 Kinase in Regulation of FLIP Expression
James W. Mier, MD
Beth Israel Deaconess Medical Center |
3:05
pm – 3:30 pm |
Tumors
Alter Sensitivity of T Cells to Apoptosis; Role of Bcl-2 Family Members
and Mitochondrial Damage
James H. Finke, PhD
Cleveland Clinic Foundation |
3:30
pm – 3:50 pm |
Refreshment
Break |
3:50
pm – 4:05 pm |
Immunological
Analysis of a Phase I/II Study of Vaccination with a MAGE-3 Protein
Plus Immunological Adjuvant AS02B in Patients with MAGE-3-Positive
Tumors
Maryse Gueguen, PhD
GlaxoSmithKline Biologicals SA |
4:05
pm – 4:20 pm |
Immunological
and Clinical Responses to a Melanoma Peptide Vaccine Administered
in Conjunction with Low-Dose Interleukin-2
Craig Slingluff, MD
University of Virginia |
4:20
pm – 4:35 pm |
Chimeric
Costimulatory Molecules that Selectively Act Through CD28 or CTLA-4
on T Cells
Margaret Neighbors, PhD
Maxygen |
4:35
pm – 4:50 pm |
Analysis
of Immune Escape Mechanism of Cancer-Possible Role of Endogenous Polyamine
Toshihiko Torigoe, MD, PhD
Sapporo Medical University |
4:50
pm – 5:05 pm |
Transforming
Growth Factor-Beta Inhibits the Antigen Presenting Functions and Anti-Tumor
Activity of Dendritic Cell Vaccines
James J. Kobie
University of Arizona
|
5:00
pm -7:00 pm |
Cocktail
Reception in Exhibit Hall
Sponsored by a grant from |